Valaciclovir
- Generic Name
- Valaciclovir
- Brand Names
- Valtrex
- Drug Type
- Small Molecule
- Chemical Formula
- C13H20N6O4
- CAS Number
- 124832-26-4
- Unique Ingredient Identifier
- MZ1IW7Q79D
- Background
Valaciclovir (valacyclovir), also known as Valtrex, is an antiviral drug that has been used to manage and treat various herpes infections for more than 2 decades. It was initially approved by the FDA in 1995 and marketed by GlaxoSmithKline . Valacyclovir is the L-valine ester of aciclovir. It is a member of the purine (guanine) nucleoside analog drug class ...
- Indication
Valacyclovir is a nucleoside analog DNA polymerase inhibitor indicated for :
Adults
• Cold Sores (Herpes Labialis)
• Genital Herpes
• Treatment of genital herpes lesions in immunocompetent patients (initial or recurrent episode)
• Suppression of genital herpes lesions in immunocompetent or HIV-infected patients
• Reduction of viral transmission
...
- Associated Conditions
- Chickenpox, Genital Herpes, Genital herpes, initial episode, Herpes Labialis, Herpes Zoster, Recurrent Genital Herpes (RGH)
- Associated Therapies
- Suppression of Recurrent Genital Herpes (RGH)
Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir
- First Posted Date
- 2002-03-07
- Last Posted Date
- 2012-06-12
- Target Recruit Count
- 91
- Registration Number
- NCT00031486
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸St. Joseph's Hospital and Medical Center - Barrow Neurological Institute - Phoenix, Phoenix, Arizona, United States
🇺🇸University of California Davis Medical Center, Sacramento, California, United States
Randomized Study of Two Doses of Oral Valacyclovir in Immunocompromised Patients With Uncomplicated Herpes Zoster
- Conditions
- First Posted Date
- 2000-08-04
- Last Posted Date
- 2007-05-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Target Recruit Count
- 66
- Registration Number
- NCT00006131
- Locations
- 🇺🇸
Center for Clinical Studies, Houston, Texas, United States
Valaciclovir to Prevent Transmission of Herpes Simplex Virus
- Conditions
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 180
- Registration Number
- NCT00001649
- Locations
- 🇺🇸
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.